Information for COVID-19 Therapeutics Providers

This page contains information and resources for Texas COVID-19 therapeutics providers. Providers with questions can contact therapeutics@dshs.texas.gov or call Provider Support at 833‑832‑7068, option 0.

On this page:

• News & Updates
• Provider Resources & Training
• How to Become a COVID-19 Therapeutics Provider
• Texas COVID-19 Product Availability
• Therapeutics Products
• Billing & Coding Information

News & Updates

More Provider Notices

• 1/03/22 DSHS letter to providers: Update on monoclonal antibodies (mAbs) and the Omicron variant (PDF)
• 12/31/21 CDC Health Alert Network (HAN) communication: Update on using therapeutics to prevent and treat COVID-19
• 12/29/21 DSHS letter to providers: Recently authorized LAAB and oral antiviral therapeutics for COVID-19 (PDF)
• 12/23/21 DSHS letter to providers: Pause of bamlanivimab/etesevimab and REGEN-COV (PDF)

Weekly eDigests (PDFs)

• 1/17/22 Weekly eDigest: HHS Therapeutics Locator; HCPCS Code for Outpatient Remdesivir; Created vs. Exported Status in VAOS; Reminder: Sotrovimab TeleTracking Reporting Requirements; etc.
• 1/10/22 Weekly eDigest: BAM/ETE and REGEN-COV Not Effective Against Omicron Variant; Paxlovid and Molnupiravir Distribution and Use; EVUSHELD Distribution and Use; etc.

How to Become a COVID-19 Therapeutics Provider

To order COVID-19 therapeutics, providers must have an AmerisourceBergen Account and have access to the Vaccine Allocation Ordering System (VAOS).

For more information on the enrollment process, please review the COVID-19 Therapeutics Enrollment Guide (PDF).

If you have any questions or issues, please email therapeutics@dshs.texas.gov or call Provider Support at 833‑832‑7068, option 0.

Therapeutics Products

Click on any of the buttons below to access a list of product-specific resources.

For the latest information on product distribution across the state, see the Texas COVID-19 Product Availability section.

Monoclonal Antibody (mAb) Products

Bamlanivimab + Etesevimab (Lilly) Casirivimab + Imdevimab (Regeneron) Sotrovimab (GlaxoSmithKline)

Long-Acting Antibody (LAAB) Product

Evusheld: tixagevimab + cilgavimab (AstraZeneca)

Oral Antiviral Products

Molnupiravir (Merck) Paxlovid: nirmatrelvir + ritonavir (Pfizer)

Provider Resources & Training

Important Links

• COVID-19 Treatment Guidelines: Anti-SARS-CoV-2 Monoclonal Antibodies (NIH)
• NIH Statement on Therapies for High-Risk, Nonhospitalized Patients
• NIH Statement on Patient Prioritization for Outpatient Therapies
• NIH Statement on Evusheld for Pre-Exposure Prophylaxis
• SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests (FDA)
• COVID-19 Therapeutics (ASPR)
• Side-by-Side Overview of COVID-19 Therapeutics (ASPR)
• COVID-19 Therapeutics Decision Aid (ASPR)

Job Aids & FAQs

• Ordering COVID-19 Therapeutics in VAOS – Job Aid (PDF, released 9/24/2021)
• Therapeutics Product Guide – Job Aid (PDF, released 1/21/2022)
• FAQs for Therapeutics Providers (PDF, V.3.0, released 11/30/2021)

Webinars

• CDC COCA Call (1/12/2022): What Clinicians Need to Know About the New Oral Antiviral Medications
• National Office Call Sessions: HHS / ASPR Allocation, Distribution, Administration of COVID-19 Therapeutics. Tuesdays and Thursdays 1:00-1:45 PM central. Please email COVID19Therapeutics@HHS.gov to request Zoom links for these calls.
• HHS Therapeutics 201 Webinar: Every other week HHS hosts a Therapeutics 201 webinar designed for sites that are new to monoclonal antibodies, email COVID19Therapeutics@HHS.gov for more information on webinar dates and registration links.

Texas COVID-19 Product Availability

• U.S. HHS COVID-19 Public Therapeutic Locator
• COVID-19 Monoclonal Antibody Availability Map

Billing & Coding Information

• Centers for Medicare and Medicaid Services Provider Toolkit
• COVID-19 Frequently Asked Questions (FAQs) on Medicare Fee-for-Service (FFS) Billing
• CMS Monoclonal Antibody COVID-19 Infusion
• CMS Oral Antiviral Guidance
• CMS Medicare Part B Payment for COVID-19 Vaccines and Certain Monoclonal Antibodies
• U.S. HRSA COVID-19 Claims Reimbursement for Testing, Treatment, and Vaccine for the Uninsured

▲ Top